Each month, the technology company IBM releases a podcast called “Wild Ducks,” focusing on world-changing people and ideas. For the month of July, IBM came to UNC Lineberger Comprehensive Cancer Center to learn about personalized medicine and meet their newest Wild Duck – Ned Sharpless, MD, UNC Lineberger Director and Wellcome Distinguished Professor in Cancer Research at the UNC School of Medicine.
UNC Lineberger will be one of more than a dozen leading cancer centers tapping IBM’s Watson to accelerate DNA analysis and inform personalized treatment options for patients. The project is part of IBM’s broader Watson Health initiative to advance patient-centered care and improve health.
Charles M. Perou, PhD, professor of genetics and pathology at the University of North Carolina School of Medicine and the basic science leader of the UNC Lineberger Comprehensive Cancer Center Breast Cancer Research Program, has been acknowledged as a health care innovator by the Triangle Business Journal. During an awards ceremony on Thursday, Perou was selected from a pool of candidates as the finalist in the 2015 TBJ Health Care Heroes – Innovator category.
Hepatitis C virus infection is a common cause of liver disease and of liver cancer in the United States. Through a new study that explores one aspect of how the virus hijacks host cell machinery to replicate itself, UNC Lineberger Comprehensive Cancer Center researchers have gained insight into the workings of a potential drug target for hepatitis C.
A study co-led by a UNC Lineberger Comprehensive Cancer Center researcher has identified genomic changes in head and neck cancers linked to the sexually transmitted disease HPV — the latest finding of a collaborative scientific effort designed to map out the genomic changes driving cancer.
Research led by UNC Lineberger Comprehensive Cancer Center members Katherine Hoadley, PhD, research assistant professor in genetics and Chuck Perou, PhD, professor of genetics and pathology, was selected by the American Society of Clinical Oncology for inclusion in Clinical Cancer Advances 2015, the Society’s annual review of progress against cancer and emerging trends in the field. The study, a comprehensive tumor genetic analysis which revealed a new way of classifying cancers, is featured as one of the year’s major achievements in clinical cancer research and care.